IL-6 Recombinant Protein
- Known as:
- Interleukin-6 Recombinant Protein
- Catalog number:
- ZR-40-523
- Product Quantity:
- 0.02 mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- IL-6 Recombinant Protein
Related genes to: IL-6 Recombinant Protein
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: IL-6 Recombinant Protein
Related articles to: IL-6 Recombinant Protein
- The impact of continuous renal replacement therapy (CRRT) with oXiris hemofilter (oXiris CRRT) on sepsis outcomes remain controversial. We aimed to investigate the association between the oXiris CRRT and subsequent outcomes in adult patients with septic shock. - Source: PubMed
Publication date: 2026/06/24
Jiang XiaofangZhang LuobeiYou JinghongMa JingZhang YantingHu ChangPeng ZhiyongLiu Chang - Atherosclerosis is characterized by lipid deposition, chronic inflammation, and apoptosis within the arterial wall, leading to plaque progression and instability. Current lipid-lowering therapies fail to fully address residual cardiovascular risk driven by local inflammation and cell death. Here, we report the development of uPA-functionalized, rapamycin-encapsulated dendrimer nanoparticles (G5PM-uPA/RA) that preferentially accumulate in urokinase plasminogen activator receptor (uPAR)-enriched atherosclerotic plaque, including macrophage- and apoptosis-rich lesion microenvironments. G5PM-uPA/RA was constructed by cross-linking reaction-enabled flash nanoprecipitation in a custom-made multi-inlet vortex mixer, followed by thiol-maleimide conjugation of uPA for uPAR-guided targeting. The nanoparticles demonstrated uniform morphology, favorable stability, and efficient rapamycin loading. In vitro, G5PM-uPA/RA exhibited enhanced macrophage uptake (1.3-fold than nontargeted form), sustained intracellular drug retention (2.2-fold than free drug), and effective suppression of inflammatory cytokine TNF-α release (-10%). In vivo biodistribution studies in mice confirmed accumulation of G5PM-uPA/RA in aortic lesions. Four weeks of G5PM-uPA/RA treatment in mice led to significant reduction in plaque burden (-52% in whole aorta, -41% in aortic root), necrotic core size (-68%), proinflammatory cytokines (-59% for TNF-α, -57% for IL-6), and apoptosis (-61%), while promoting fibrous cap thickening (+60%). Importantly, systemic toxicity was not observed. Collectively, these findings demonstrate that G5PM-uPA/RA offers an effective and safe strategy for inflammation modulation and plaque stabilization, providing a promising nanomedicine platform for atherosclerosis therapy. - Source: PubMed
Publication date: 2026/06/24
Chuang Hsin-YinKou HuariHuang Yue-WernYang Hu - Diabetic nephropathy (DN) is one of the severe complications of diabetes. The specific roles and mechanisms of lncRNAs in DN remain to be further elucidated. This study aimed to investigate whether lncRNA RAD51-AS1 participates in oxidative stress and inflammatory responses in DN by regulating the miR-154-5p/MPC2 axis, and to elucidate its potential molecular mechanisms. - Source: PubMed
Publication date: 2026/06/24
Pu MengmengChen YijunOuyang Dewei - Sarcopenia, assessed via computed tomography (CT), is an emerging prognostic tool in critically ill, pulmonary, and geriatric patients. Laboratory inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR) are routinely obtained in these populations. Whether CT-assessed sarcopenia combined with laboratory markers offers superior prognostic accuracy over either measure alone remains unclear. - Source: PubMed
Elgazzar Yumna AAbdelrazek MohamedGhozzy Omar Ahmed MohamedMashhour KarimElhady Mona AhmedAmro Ola Abd Elfattah AliMokhtar Hwaida MahmoudAbdellatif Khaled Adel KhairyMohamed Mahmoud MostafaAlsharif Mohammed BMawkili HamzahHendi Ali MDhayihi Turki MohammedAdawy ZeinabAli Rahma Farghaly - Clinical heterogeneity exists among individuals with elevated lipoprotein(a) [Lp(a)] levels. Prior studies suggest that low-grade inflammation may modify this risk, but results remain conflicting. - Source: PubMed
Publication date: 2026/06/24
Mohammadnia NiekbachshLi LinkeEzzat DanielYu ZhiRaghu Vineet KHalford Jennifer LRiksen Niels PNatarajan PradeepCornel Jan HHonigberg Michael CEl Messaoudi Saloua